Sionna Therapeutics (NASDAQ:SION) Director Sells $2,165,637.06 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 48,546 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $44.61, for a total transaction of $2,165,637.06. Following the completion of the sale, the director owned 2,916,228 shares of the company’s stock, valued at $130,092,931.08. This trade represents a 1.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Orbimed Advisors Llc also recently made the following trade(s):

• On Monday, May 11th, Orbimed Advisors Llc sold 184,639 shares of Sionna Therapeutics stock. The shares were sold at an average price of $46.22, for a total transaction of $8,534,014.58.
• On Friday, May 8th, Orbimed Advisors Llc sold 59,767 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.58, for a total transaction of $2,664,412.86.
• On Saturday, April 18th, Orbimed Advisors Llc sold 2,948 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.52, for a total transaction of $131,244.96.
• On Friday, April 17th, Orbimed Advisors Llc sold 52,397 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.68, for a total transaction of $2,341,097.96.
• On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The shares were sold at an average price of $45.34, for a total transaction of $10,287,918.04.
• On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.64, for a total transaction of $10,528,924.32.
• On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.51, for a total transaction of $2,128,201.14.

Sionna Therapeutics Trading Up 3.9%

SION stock traded up $1.72 during mid-day trading on Monday, hitting $45.95. 670,726 shares of the company were exchanged, compared to its average volume of 344,329. The business has a 50 day simple moving average of $38.55 and a 200-day simple moving average of $39.36. The stock has a market capitalization of $2.07 billion, a PE ratio of -23.56 and a beta of 1.35. Sionna Therapeutics, Inc. has a 1-year low of $11.77 and a 1-year high of $48.45.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.15. Equities research analysts expect that Sionna Therapeutics, Inc. will post -2.32 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. TD Asset Management Inc raised its position in Sionna Therapeutics by 74.3% during the third quarter. TD Asset Management Inc now owns 87,082 shares of the company’s stock valued at $2,561,000 after purchasing an additional 37,116 shares in the last quarter. Jennison Associates LLC raised its position in Sionna Therapeutics by 11.8% during the fourth quarter. Jennison Associates LLC now owns 1,115,278 shares of the company’s stock valued at $45,883,000 after purchasing an additional 117,903 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Sionna Therapeutics during the third quarter valued at approximately $147,000. Artia Global Partners LP acquired a new position in Sionna Therapeutics during the fourth quarter valued at approximately $4,926,000. Finally, Eventide Asset Management LLC acquired a new position in Sionna Therapeutics during the fourth quarter valued at approximately $26,290,000.

Analysts Set New Price Targets

SION has been the subject of several research reports. Citizens Jmp initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 price objective for the company. Lifesci Capital upgraded shares of Sionna Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a research report on Friday. BTIG Research reiterated a “buy” rating and issued a $58.00 price target on shares of Sionna Therapeutics in a research report on Monday, April 27th. Finally, Citigroup began coverage on shares of Sionna Therapeutics in a research report on Tuesday, February 24th. They issued an “outperform” rating for the company. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $53.00.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.